Lenore Buckley, MD, MPH
Professor of Medicine (Rheumatology, Allergy & Immunology) and of Pediatrics (General Pediatrics)Cards
About
Research
Overview
Medical Research Interests
Lupus Erythematosus, Systemic; Osteoporosis, Postmenopausal
Publications
2019
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
Buckley L, Suarez‐Almazor M. Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer? Arthritis & Rheumatology 2019, 71: 1971-1973. PMID: 31379056, DOI: 10.1002/art.41064.Peer-Reviewed Original Research
2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment
2016
Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome
Wallace N, Dumont A, Burns A, Christopher T, Rinder H, Kriegel M, Buckley L, Erkan D, Lee A. Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. Blood 2016, 128: 4983. DOI: 10.1182/blood.v128.22.4983.4983.Peer-Reviewed Original ResearchLupus anticoagulant-hypoprothrombinemia syndromePartial thromboplastin timeAntiphospholipid syndromeImmune thrombocytopeniaAntiphospholipid antibodiesAPS patientsProthrombin timeCessation of anticoagulationGlycoprotein 1 antibodiesObstetrical antiphospholipid syndromeRole of thromboelastographySevere hemorrhagic complicationsSpecific coagulation defectsCatastrophic antiphospholipid syndromeChronic liver diseaseGlobal hemostasis assaysTraditional laboratory markersBaseline prolongationChronic aspirinPersistent positivityAdrenal hemorrhageAnticardiolipin antibodiesHemorrhagic complicationsImmunomodulatory treatmentAnticardiolipin IgG
2009
Reply
Desai S, Solomon D, Abramson S, Buckley L, Crofford L, Cush J, Lovell D, Saag K, Drugs A. Reply. Arthritis & Rheumatism 2009, 61: 285-286. DOI: 10.1002/art.24171.Peer-Reviewed Original Research
2001
Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy
Stern A, Riley R, Buckley L. Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy. JCR Journal Of Clinical Rheumatology 2001, 7: 252-256. PMID: 17039144, DOI: 10.1097/00124743-200108000-00013.Peer-Reviewed Original ResearchMacrophage activation syndromeActivation syndromeSoluble tumor necrosis factor-alpha receptorEpstein-Barr virus infectionNonsteroidal anti-inflammatory drugsChildhood rheumatic disordersDramatic clinical improvementUse of etanerceptTumor necrosis factor-alpha receptorPeriod of feverAnti-inflammatory drugsEtanercept therapyClinical improvementPulse corticosteroidsLymph nodesParenteral goldRheumatic disordersClinical syndromeHistopathological examinationAdult onsetVirus infectionInfectious processPharmacological agentsBone marrowMononuclear phagocytes
2000
Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition
Buckley L, Sanders K, Shih M, Kallar S, Hampton C. Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition. Academic Medicine 2000, 75: 283-288. PMID: 10724319, DOI: 10.1097/00001888-200003000-00021.Peer-Reviewed Original Research
1999
Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey
Buckley L, Marquez M, Feezor R, Ruffin D, Benson L. Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey. Arthritis & Rheumatism 1999, 42: 1736-1739. PMID: 10446875, DOI: 10.1002/1529-0131(199908)42:8<1736::aid-anr24>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsBone density testingCorticosteroid-induced osteoporosisCorticosteroid treatmentPreventive treatmentLong-term oral corticosteroid treatmentLong-term corticosteroid usersLong-term corticosteroid treatmentDensity testingMean prednisone doseOral corticosteroid treatmentBone density testHormone replacement therapyPrimary care physiciansStandard of careCorticosteroid usersPMP womenPrednisone dosePostmenopausal womenBisphosphonate treatmentCare physiciansOsteoporosis preventionBone lossReplacement therapyCalcium supplementsPatient survey
1998
Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis
Hudson J, Small R, Buckley L. Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis. Journal Of The American Pharmacists Association 1998, 38: 710-716. PMID: 9861789, DOI: 10.1016/s1086-5802(16)30392-8.Peer-Reviewed Original ResearchConceptsCorticosteroid therapyPerceptions of pharmacistsCorticosteroid usePostmenopausal womenPremenopausal womenAdverse effectsPatient counselingHigh-dose corticosteroid useWeight gainCorticosteroid-induced osteoporosisHigh-dose corticosteroidsHigh-dose therapyDrug-induced complicationsPrevention of osteoporosisPrednisone useBone densityOsteoporosisHospital pharmacistsMailed surveyTherapyMood changesPharmacistsWomenRespondents' knowledgeCorticosteroidsVariations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
Buckley L, Marquez M, Hudson J, Downs R, Vacek P, Small R, Poses R. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. The Journal Of Rheumatology 1998, 25: 2195-202. PMID: 9818664.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyCorticosteroid treatmentPhysician judgmentCorticosteroid usePhysician specialtySide effectsPostmenopausal patientsVitamin DBone lossReplacement therapyCorticosteroid-induced osteoporosisImportance of osteoporosisVitamin D supplementationMajority of patientsRisk of osteoporosisPrimary care physiciansSignificant side effectsHypothetical clinical scenariosImportance of corticosteroidsEfficacy of treatmentD supplementationPostmenopausal womenPremenopausal womenPhysician assessmentCare physicians
1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain items
Clinical Care
Overview
Lenore Buckley, MD, is an adult and pediatric rheumatologist with a particular focus on treating lupus, inflammatory arthritis, and glucocorticoid-induced osteoporosis. She is also dedicated to facilitating the transition of teenagers and young adults with rheumatic diseases to adult care, ensuring continuity and quality of care for her patients.
In addition to clinical practice, Dr. Buckley is a professor of medicine at Yale School of Medicine. Her research interests include the effects of calcium and vitamin D supplements on bone density in patients treated with corticosteroids, as well as the safety and efficacy of disease-modifying drugs in rheumatoid arthritis. Her work has contributed valuable insights into the management of these conditions, enhancing the understanding of drug safety and the role of supplements in bone health.
Dr. Buckley earned her medical degree from the University of Rochester. She completed her residency in internal medicine and pediatrics at North Carolina Memorial Hospital, followed by a fellowship in rheumatology at the University of Vermont College of Medicine.
Clinical Specialties
Rheumatology
Board Certifications
Rheumatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1984
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 1983
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1981
News
News
- January 28, 2025
Yale Faculty Contribute to National Interstitial Lung Disease Guideline
- August 29, 2024Source: Everyday Health
Immunosuppressant Drugs for Psoriatic Arthritis
- October 27, 2022
Dr. Linda Bockenstedt and Dr. Richard Bucala Named ACR Masters
- October 22, 2021
Providing Health Care Accessibility for People with Rheumatic Disease in New Haven
Get In Touch
Contacts
Administrative Support
Locations
Yale Rheumatology
Academic Office
The Anlyan Center
300 Cedar Street, Fl 2nd floor, Ste TAC, Rm S-217
New Haven, CT 06519
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.